Clinical Studies Sponsored by Emergent BioSolutions

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)	NCT00928577	Smallpox	2008	2015	Observational
‌ Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults	NCT01491607	Anthrax	2011	2012	Interventional
‌ Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel	NCT01540929	Smallpox	2009	2012	Observational
‌ ACAM2000® Myopericarditis Registry	NCT01395082	Myocarditis Pericarditis	2011	February 4, 2019	Observational
‌ Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)	NCT01202695	Anthrax	2010	2011	Interventional
‌ Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum	NCT00448253		2007	2008	Interventional
‌ Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)	NCT03624946		June 27, 2018	March 6, 2019	Interventional
‌ Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults	NCT05935917	Smallpox	May 30, 2023	September 27, 2023	Interventional
‌ Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax	NCT03569514	Anthrax	February 11, 2024	2025	Observational
‌ A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients	NCT03569553		February 11, 2024	2025	Observational
‌ A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults	NCT04661839	COVID-19	December 24, 2020	July 27, 2021	Interventional
‌ BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin	NCT02055183	Botulism	2014	2017	Observational
‌ VELOCITY: An Anthrax Vaccine Clinical Study	NCT03877926	‌ Anthrax	March 11, 2019	August 6, 2020	Interventional
‌ Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)	NCT00845650	Anthrax	2009	2010	Interventional
‌ VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV	NCT01158157		September 13, 2010	February 14, 2012	Interventional
‌ A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines	NCT01979406		2013	2015	Interventional
‌ Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses	NCT00360737	‌ Healthy	2006	2010	Interventional
‌ Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects	NCT02061358		2014	2015	Interventional
‌ Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults	NCT05377255	Opioid overdose	March 28, 2022	May 10, 2022	Interventional
‌ Ciprofloxacin BioThrax Co-Administration Study	NCT01753115	‌ Anthrax	2012	2013	Interventional
‌ Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults	NCT00053482	Smallpox	2003	2003	Interventional
‌ Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination	NCT00053495	Smallpox	2003	2003	Interventional
‌ A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047	NCT03160339		May 1, 2017	November 27, 2017	Interventional
‌ Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants	NCT02771730	HIV vaccine	2015	2019	Interventional
‌ Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis	NCT02177721		2021	2025	Interventional

Results per page:

37 results

0 selected

37 results

0 selected